Distillate Capital Partners LLC Purchases 1,616 Shares of Johnson & Johnson $JNJ

Distillate Capital Partners LLC boosted its position in shares of Johnson & Johnson (NYSE:JNJ) by 0.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 283,609 shares of the company’s stock after buying an additional 1,616 shares during the period. Johnson & Johnson accounts for about 2.3% of Distillate Capital Partners LLC’s portfolio, making the stock its 3rd largest holding. Distillate Capital Partners LLC’s holdings in Johnson & Johnson were worth $43,321,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. GFG Capital LLC purchased a new position in Johnson & Johnson in the 2nd quarter valued at $35,000. Stone House Investment Management LLC acquired a new stake in shares of Johnson & Johnson in the first quarter valued at about $47,000. 1248 Management LLC purchased a new position in shares of Johnson & Johnson in the first quarter worth about $48,000. Vermillion & White Wealth Management Group LLC grew its stake in Johnson & Johnson by 66.4% during the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 376 shares of the company’s stock valued at $57,000 after acquiring an additional 150 shares in the last quarter. Finally, Pandora Wealth Inc. acquired a new stake in Johnson & Johnson in the 1st quarter valued at about $65,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the sale, the executive vice president owned 178,013 shares of the company’s stock, valued at $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Performance

NYSE JNJ opened at $206.89 on Monday. The stock has a fifty day simple moving average of $191.33 and a 200-day simple moving average of $173.72. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50. The stock has a market cap of $498.46 billion, a PE ratio of 19.97, a P/E/G ratio of 2.19 and a beta of 0.38. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $207.81.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. The firm had revenue of $24.02 billion for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. Equities analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be given a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.5%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 50.19%.

Wall Street Analysts Forecast Growth

JNJ has been the topic of several recent research reports. Scotiabank started coverage on Johnson & Johnson in a report on Thursday, November 13th. They set a “sector outperform” rating and a $230.00 target price on the stock. Citigroup boosted their price objective on Johnson & Johnson from $213.00 to $215.00 and gave the stock a “buy” rating in a research note on Wednesday, October 15th. Argus set a $210.00 target price on Johnson & Johnson in a report on Wednesday, October 15th. Bank of America lifted their price target on Johnson & Johnson from $198.00 to $204.00 and gave the stock a “neutral” rating in a report on Wednesday, October 15th. Finally, Weiss Ratings restated a “buy (b)” rating on shares of Johnson & Johnson in a research report on Friday, October 31st. Four investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $201.05.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.